Bayer changes tune on fate of pharma unit. (News).(Bayer AG drops insistance on majority control of pharmaceutical partnership)

Chemical Market Reporter, November, 2002

BAYER AG has lifted a major barrier to the merger of its pharmaceutical unit with another drugmaker by dropping its insistence on majority control of a pharmaceutical partnership. "A possible partnership must not be prevented by rigid insistence on Bayer having a certain shareholding," Werner Wenning, Bayer's chairman, told a press conference at Leverkusen, Germany, last week.

"We can no longer realistically expect Bayer to have a majority interest in a partnership that would, at the same time, benefit our business." Mr. Wenning hints that the company's preferred option could be a 50/50 joint venture with another drug manufacturer, most likely in Europe. "I am talking about neither a minority or majority shareholding solution," he says. "I will not...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement
Click Here